Medical
-
The Allergy and Asthma Network Mothers of Asthmatics (AANMA) has published results of a new survey of US asthma patients. Of the patients surveyed, 100% reported use of a short-acting bronchodilator, and 95% reported that… Read more . . .
-
An article published in the March 17, 2011 issue of the New England Journal of Medicine details a study by researchers from the Boston University School of Medicine showing that omalizumab reduces the need for… Read more . . .
-
After a favorable end-of-Phase 2 meeting with the FDA, St. Renatus has announced that it plans to proceed to Phase 3 studies of its dental anesthetic, which is delivered as a nasal mist via a… Read more . . .
-
German biopharmaceutical company Revotar has announced that its Bimosiamose inhalation solution for the treatment of COPD met its primary endpoint in a Phase 2 study involving more than 75 patients with moderate-to-severe COPD. Bimosiamose is… Read more . . .
-
The COPD Foundation has announced that COPD: Journal of Chronic Obstructive Pulmonary Disease will be its official journal. According to John W Walsh, President of the COPD Foundation, “COPD: Journal of Chronic Obstructive Pulmonary Disease,… Read more . . .
-
The Asthma and Allergy Foundation of America (AAFA) has published its annual list of US “asthma capitals,” led this year by Richmond, Virginia. The list ranks 100 metropolitan areas in terms of difficulties that they… Read more . . .
-
A dosage trial of Verona Pharma’s inhaled mixed phosphodiesterase (PDE) 3/4 inhibitor RPL554 for the treatment of mild asthma has demonstrated positive bronchodilation without any significant adverse effects at dosages two and four times higher… Read more . . .
-
A review study published in The Cochrane Library finds that inhaled epinephrine provides significant relief of croup symptoms in children within 30 minutes compared to placebo. The review included 8 studies involving 225 children. Read… Read more . . .
-
Teva’s Qnaze beclomethasone nasal aerosol has met all efficacy endpoints in a Phase III trial. The study involved 470 patients with perennial allergic rhinitis. After 6 weeks of treatment, patients using the product experienced significant… Read more . . .
-
An article in the January 31, 2011 issue of PNAS describes how rhesus macaques gained protection against the measles virus after inhalation of a single dose of a dry powder live attenuated measles vaccine (LAMV).… Read more . . .

Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here

